HER2 as a Prognostic Factor in Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|61|2|67-72

ISSN： 0030-2414

Source： Oncology, Vol.61, Iss.2, 2001-10, pp. : 67-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER2: The Neu Prognostic Marker for Breast Cancer

By Tsongalis Gregory J.   Ricci Jr. Andrew  

Critical Reviews in Clinical Laboratory Sciences, Vol. 38, Iss. 2, 1998-03 ,pp. : 167-182

Informa Healthcare

Access to resources Recommend Favorite

Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

By  

Oncology Research and Treatment, Vol. 36, Iss. 10, 2013-09 ,pp. : 554-558

Karger

Access to resources Recommend Favorite

Stage IV breast cancer: a population‐based study about prognostic factors according to HER2 and HR status

By  

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 6, 2015-11 ,pp. : 920-928

John Wiley & Sons Inc

Access to resources Recommend Favorite

Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 116, Iss. 8, 2017-12 ,pp. : 1021-1028

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 111-116

Bentham Science Publishers

Access to resources Recommend Favorite